
Otsuka Pharmaceutical Presents New Phase 3 Centanafadine ADHD Data at the ASCP Annual Meeting
Otsuka Pharmaceutical Development & Commercialization Presents New Phase 3 Centanafadine Analyses Highlighting Broader ADHD Symptom Improvements Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Development & Commercialization unveiled new post hoc exploratory analyses from two pivotal Phase 3 clinical studies evaluating…












